Abstract
A multidisciplinary, fragment-based screening approach involving protein ensemble docking and biochemical and NMR assays is described. This approach led to the discovery of several structurally diverse, neutral surrogates for cationic factor VIIa P1 groups, which are generally associated with poor pharmacokinetic (PK) properties. Among the novel factor VIIa inhibitory fragments identified were aryl halides, lactams, and heterocycles. Crystallographic structures for several bound fragments were obtained, leading to the successful design of a potent factor VIIa inhibitor with a neutral lactam P1 and improved permeability.
Publication types
-
Research Support, Non-U.S. Gov't
-
Research Support, U.S. Gov't, Non-P.H.S.
MeSH terms
-
Blood Coagulation / drug effects
-
Crystallography, X-Ray
-
Drug Design*
-
Factor VIIa / antagonists & inhibitors*
-
Factor VIIa / metabolism
-
Halogens / chemistry
-
Halogens / pharmacology
-
Heterocyclic Compounds / chemistry
-
Heterocyclic Compounds / pharmacology
-
Humans
-
Lactams / metabolism
-
Lactams / pharmacology
-
Models, Molecular
-
Molecular Docking Simulation
-
Serine Proteinase Inhibitors / chemistry*
-
Serine Proteinase Inhibitors / pharmacology*
Substances
-
Halogens
-
Heterocyclic Compounds
-
Lactams
-
Serine Proteinase Inhibitors
-
Factor VIIa